Literature DB >> 24792489

Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.

Ahsan S Farooqi1, Rebecca A Dagg, L Mi Rim Choi, Jerry W Shay, C Patrick Reynolds, Loretta M S Lau.   

Abstract

Alternative lengthening of telomeres (ALT) is a telomerase-independent telomere length maintenance mechanism that enables the unlimited proliferation of a subset of cancer cells. Some neuroblastoma (NB) tumors appear to maintain telomere length by activating ALT. Of 40 NB cell lines, we identified four potential ALT cell lines (CHLA-90, SK-N-FI, LA-N-6, and COG-N-291) that were telomerase-negative and had long telomeres (a feature of ALT cells). All four cell lines lacked MYCN amplification and were p53 non-functional upon irradiation. Two of these cell lines (CHLA-90 and SK-N-FI) were positive for C-circles (telomeric DNA circles) and ALT-associated promyelocytic leukemia nuclear bodies, both of which are phenotypic characteristics of ALT. Mutation of ATRX (associated with ALT in tumors) was only found in CHLA-90. Thus, the ALT phenotype in NB may not be limited to tumors with ATRX mutations but is associated with a lack of MYCN amplification and alterations in the p53 pathway.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24792489     DOI: 10.1007/s11060-014-1456-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  47 in total

1.  Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells.

Authors:  K Perrem; L M Colgin; A A Neumann; T R Yeager; R R Reddel
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

2.  Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes.

Authors:  Jan J Molenaar; Jan Koster; Danny A Zwijnenburg; Peter van Sluis; Linda J Valentijn; Ida van der Ploeg; Mohamed Hamdi; Johan van Nes; Bart A Westerman; Jennemiek van Arkel; Marli E Ebus; Franciska Haneveld; Arjan Lakeman; Linda Schild; Piet Molenaar; Peter Stroeken; Max M van Noesel; Ingrid Ora; Evan E Santo; Huib N Caron; Ellen M Westerhout; Rogier Versteeg
Journal:  Nature       Date:  2012-02-22       Impact factor: 49.962

Review 3.  Alternative lengthening of telomeres: models, mechanisms and implications.

Authors:  Anthony J Cesare; Roger R Reddel
Journal:  Nat Rev Genet       Date:  2010-03-30       Impact factor: 53.242

4.  Telomerase activity distinguishes between neuroblastomas with good and poor prognosis.

Authors:  C Poremba; H Willenbring; B Hero; H Christiansen; K L Schäfer; C Brinkschmidt; H Jürgens; W Böcker; B Dockhorn-Dworniczak
Journal:  Ann Oncol       Date:  1999-06       Impact factor: 32.976

Review 5.  Alternative lengthening of telomeres in mammalian cells.

Authors:  Jeremy D Henson; Axel A Neumann; Thomas R Yeager; Roger R Reddel
Journal:  Oncogene       Date:  2002-01-21       Impact factor: 9.867

Review 6.  Telomeres: protecting chromosomes against genome instability.

Authors:  Roderick J O'Sullivan; Jan Karlseder
Journal:  Nat Rev Mol Cell Biol       Date:  2010-02-03       Impact factor: 94.444

7.  Telomeres shorten during ageing of human fibroblasts.

Authors:  C B Harley; A B Futcher; C W Greider
Journal:  Nature       Date:  1990-05-31       Impact factor: 49.962

8.  Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse.

Authors:  Jane Carr; Emma Bell; Andrew D J Pearson; Ursula R Kees; Helen Beris; John Lunec; Deborah A Tweddle
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

9.  Correlating telomerase activity levels with human neuroblastoma outcomes.

Authors:  E Hiyama; K Hiyama; T Yokoyama; Y Matsuura; M A Piatyszek; J W Shay
Journal:  Nat Med       Date:  1995-03       Impact factor: 53.440

10.  Detection of alternative lengthening of telomeres by telomere quantitative PCR.

Authors:  Loretta M S Lau; Rebecca A Dagg; Jeremy D Henson; Amy Y M Au; Janice A Royds; Roger R Reddel
Journal:  Nucleic Acids Res       Date:  2012-08-25       Impact factor: 16.971

View more
  12 in total

1.  Telomerase activation by genomic rearrangements in high-risk neuroblastoma.

Authors:  Martin Peifer; Falk Hertwig; Frederik Roels; Daniel Dreidax; Moritz Gartlgruber; Roopika Menon; Andrea Krämer; Justin L Roncaioli; Frederik Sand; Johannes M Heuckmann; Fakhera Ikram; Rene Schmidt; Sandra Ackermann; Anne Engesser; Yvonne Kahlert; Wenzel Vogel; Janine Altmüller; Peter Nürnberg; Jean Thierry-Mieg; Danielle Thierry-Mieg; Aruljothi Mariappan; Stefanie Heynck; Erika Mariotti; Kai-Oliver Henrich; Christian Gloeckner; Graziella Bosco; Ivo Leuschner; Michal R Schweiger; Larissa Savelyeva; Simon C Watkins; Chunxuan Shao; Emma Bell; Thomas Höfer; Viktor Achter; Ulrich Lang; Jessica Theissen; Ruth Volland; Maral Saadati; Angelika Eggert; Bram de Wilde; Frank Berthold; Zhiyu Peng; Chen Zhao; Leming Shi; Monika Ortmann; Reinhard Büttner; Sven Perner; Barbara Hero; Alexander Schramm; Johannes H Schulte; Carl Herrmann; Roderick J O'Sullivan; Frank Westermann; Roman K Thomas; Matthias Fischer
Journal:  Nature       Date:  2015-10-14       Impact factor: 49.962

Review 2.  Retrotransposon-derived p53 binding sites enhance telomere maintenance and genome protection.

Authors:  Paul M Lieberman
Journal:  Bioessays       Date:  2016-08-19       Impact factor: 4.345

3.  ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156.

Authors:  Balakrishna Koneru; Ahsan Farooqi; Thinh H Nguyen; Wan Hsi Chen; Ashly Hindle; Cody Eslinger; Monish Ram Makena; Trevor A Burrow; Joanne Wilson; Aaron Smith; Venkatesh Pilla Reddy; Elaine Cadogan; Stephen T Durant; C Patrick Reynolds
Journal:  Sci Transl Med       Date:  2021-08-18       Impact factor: 19.319

4.  Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.

Authors:  Balakrishna Koneru; Gonzalo Lopez; Ahsan Farooqi; Karina L Conkrite; Thinh H Nguyen; Shawn J Macha; Apexa Modi; Jo Lynne Rokita; Eduardo Urias; Ashly Hindle; Heather Davidson; Kristyn Mccoy; Jonas Nance; Vanda Yazdani; Meredith S Irwin; Shengping Yang; David A Wheeler; John M Maris; Sharon J Diskin; C Patrick Reynolds
Journal:  Cancer Res       Date:  2020-04-14       Impact factor: 12.701

Review 5.  Alpha Thalassemia/Mental Retardation Syndrome X-Linked, the Alternative Lengthening of Telomere Phenotype, and Gliomagenesis: Current Understandings and Future Potential.

Authors:  Jenny He; Alireza Mansouri; Sunit Das
Journal:  Front Oncol       Date:  2018-01-08       Impact factor: 6.244

Review 6.  Molecularly Targeted Therapy for Neuroblastoma.

Authors:  Emily G Greengard
Journal:  Children (Basel)       Date:  2018-10-15

7.  Telomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma.

Authors:  Eun Young Yu; Irene Y Cheung; Yi Feng; Mohamed O Rabie; Gail J Roboz; Monica L Guzman; Nai-Kong V Cheung; Neal F Lue
Journal:  Neoplasia       Date:  2019-05-23       Impact factor: 5.715

Review 8.  Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis.

Authors:  S Nicolai; M Pieraccioli; A Peschiaroli; G Melino; G Raschellà
Journal:  Cell Death Dis       Date:  2015-12-03       Impact factor: 8.469

9.  Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma.

Authors:  Sally L George; Federica Lorenzi; David King; Sabine Hartlieb; James Campbell; Helen Pemberton; Umut H Toprak; Karen Barker; Jennifer Tall; Barbara Martins da Costa; Marlinde L van den Boogaard; M Emmy M Dolman; Jan J Molenaar; Helen E Bryant; Frank Westermann; Christopher J Lord; Louis Chesler
Journal:  EBioMedicine       Date:  2020-08-23       Impact factor: 8.143

Review 10.  Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma.

Authors:  S L George; V Parmar; F Lorenzi; L V Marshall; Y Jamin; E Poon; P Angelini; L Chesler
Journal:  J Exp Clin Cancer Res       Date:  2020-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.